Manny's ordinary profit forecast for the fiscal year ending August 2027 was revised down 1.7% week on week to ¥10,891 million. The forecast growth rate over the previous year's actual result was reduced from 5% to 3.1%.
Manny's consensus forecast for ordinary profit fell 1.7% from ¥11,086 million the previous week to ¥10,891 million. The current consensus forecast is broadly in line with the company's forecast of ¥10,900 million. The rating consensus remains unchanged at 4.0.
The forecast for growth over the previous year's actual result was revised down from 5% to 3.1%.
The company's forecast is ¥10,900 million, and there is no significant divergence from the current consensus forecast. Market participants' assessment is considered unchanged at 4.0.
Related stocks include Daiken Medical, ASAHI INTECC, Nagaileben and Nipro.